The short answer
IGF-1 LR3 is a folded protein held by three disulfide bonds, and its principal vulnerability is loss of structure rather than chemical degradation. It can become inactive while remaining chemically intact. A failure mode short peptides do not have.
Key facts
- Class
- Folded protein, 83 residues
- Main risk
- Denaturation, not chemistry
- Detectable by MS
- No (mass is unchanged)
- Disulfide scrambling
- Possible, also mass-invisible
- Adsorption
- Significant at low concentrations
- Freeze-thaw
- Particularly damaging
The failure mode that has no peptide equivalent
KPV is three residues with no structure to lose. It is either chemically intact or it is not. A folded protein has a third state: chemically perfect and biologically inert, because the fold has been lost. No mass measurement detects this, and no purity figure describes it.
Why interfaces are the enemy
Proteins unfold at air-liquid interfaces, where the hydrophobic core that folding buries becomes exposed. Shaking creates interface; foaming is visible evidence of it. Once unfolded, a protein tends to aggregate with others, and aggregation is not reversible by remixing.
Research material referenced
IGF-1 LR3 1mg, third-party HPLC tested
Disulfide scrambling
Three disulfide bonds can, under the right conditions, exchange partners, producing a molecule with identical composition and mass but the wrong connectivity and the wrong shape. Elevated pH and the presence of free thiols promote this. It is another route to an inactive product that looks perfect analytically.
Adsorption at low concentrations
Proteins bind to glass and plastic, and at the microgram quantities this compound is used in, surface losses can be a significant fraction of the material. Carrier protein in the buffer is the standard mitigation for exactly this reason, along with low-binding consumables and minimal transfer steps.
Freeze-thaw
Worse for a folded protein than for a short peptide. Ice formation concentrates solutes at the advancing boundary, shifts local pH, and creates new interfaces on every cycle. Aliquot into single-use volumes before freezing rather than cycling a stock.
What follows from all of this
A certificate confirming mass and purity does not confirm that a protein preparation is active. For a compound whose function depends entirely on a fold, that is a real limitation of the standard documentation.
Frequently asked questions
Can IGF-1 LR3 be inactive but chemically intact?
Yes. Loss of fold produces an inactive protein with unchanged mass and composition. This has no equivalent in a short peptide.
Why does adsorption matter?
At the microgram quantities used, protein binding to glass and plastic can be a significant fraction of the material.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More IGF-1 LR3 articles
- How to Verify a Protein With No PubChem RecordIGF-1 is not in PubChem - proteins are indexed in UniProt instead. What that means for checking a certificate, and what a certificate should carry.
- IGF-1 LR3 and Anti-Doping StatusIGF-1 and its analogues sit in WADA class S2, prohibited in and out of competition. What that classification covers and why it is unconditional.
- IGF-1 LR3 Regulatory StatusNo marketing authorisation anywhere, though an approved native rhIGF-1 exists. Why that distinction is the important one in this category.
- A Natural Experiment in Absent IGF-1People with growth hormone receptor deficiency produce almost no IGF-1. Laron and Werner report that they do not develop cancer.
- A Strong Rationale That Did Not TranslateThe IGF-1 receptor was pursued as an oncology target on excellent biological grounds. The clinical programmes largely failed, and why is instructive.